The first domestic mRNA vaccine is about to be approved: Fosun Pharma's Fubitai has passed the professional review

On July 14, 2021, Fosun Pharma said in response to investor inquiries at the general meeting of shareholders that the National Food and Drug Administration has basically completed the review of the mRNA new crown vaccine "Fubitai", and the expert review has been passed and is currently being stepped up.

The Fubitai vaccine is named BNT162b2, which was developed by the German BioNTech company.

According to the results of the third phase of the global clinical trial, BioNTech's mRNA COVID-19 vaccine BNT162b2 has reached all the primary efficacy endpoints.

On July 12, 2021, Fuxing Pharmaceutical announced that its holding subsidiary Fosun Industrial has formally signed "Sales Agreements" with TSMC, Hon Hai and Yongling Foundation, and Yuli Pharmaceuticals.

If Fubitai is approved for marketing, it will become the first mRNA COVID-19 vaccine in China.

Reference materials:

[1] Fosun Pharma's official website